<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850031</url>
  </required_header>
  <id_info>
    <org_study_id>ACU-P08-020A</org_study_id>
    <nct_id>NCT00850031</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of the AcuFocus Corneal Inlay ACI 7000PDT in Presbyopes</brief_title>
  <acronym>ACI</acronym>
  <official_title>A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay (ACI)™ ACI 7000PDT in Presbyopic Subjects (OUS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AcuFocus, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AcuFocus, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will
      provide an effective method for the correction of presbyopia in patients who have normal
      distance vision but need a correction such as glasses or contact lenses to see clearly at
      near.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The loss of near vision and the ability to perform tasks that require near vision is part of
      the normal aging process. This natural transformation in the eye occurs as a result of the
      loss of accommodation of the crystalline lens, a condition known as presbyopia. The
      crystalline lens is responsible for the accommodative properties of the human eye, as
      established by Young in 1801, over 200 years ago.1 During accommodation, the ciliary muscle
      contracts, decreasing tension on the zonules, and allowing the crystalline lens to thicken,
      increasing its refractive power. This mechanism of accommodation and thickening of the lens
      provides the eye with adequate refractive power for near vision. The loss of accommodation
      with aging is the result of changes in the crystalline lens composition that prevent the
      natural accommodative process from occurring. This is associated with the gradual loss of
      near vision without external correction, generally in the form of spectacles.

      The AcuFocus™ ACI 7000PDT represents new technology based on the well-established concept of
      small-aperture optics. In early cameras, depth of focus was controlled by reducing the
      aperture through which light enters. The smaller the aperture, the greater the depth of focus
      will be. This concept also applies to the human eye. In the eye of a presbyopic emmetrope,
      the lens cannot accommodate sufficiently to focus the light rays from a near object onto a
      single point on the retina. Thus, a point object is imaged as a blur circle on the retina,
      and images of extended objects are degraded as well. If an opaque disc with a small aperture
      in the center is placed in front of the eye, the peripheral rays will be obscured while the
      central rays pass unaffected. Since peripheral rays enter the eye at a larger angle, they
      create a larger blur circle at the retinal image plane. Eliminating these peripheral rays
      reduces the size of the blur circle, improving image resolution.

      In presbyopic subjects, objects closer than arm's length are focused behind the retina, thus
      creating blurred retinal images (which are composed of blur circles). A small aperture inlay
      placed in front of the eye of these subjects allows them to see at near by reducing the size
      of the blur circle.

      AcuFocus, Inc. has developed a stationary intracorneal inlay designed to create a small
      aperture effect. The implant is intended to be placed intra-stromally either under a corneal
      flap or into a corneal pocket. Placement of the ACI will be centered over the pupil in the
      non-dominant eye. The ACI is expected to increase the depth of focus of the eye by reducing
      the circle of blur. Based on theoretical calculations of small aperture optics, the ACI is
      expected to provide presbyopic subjects with improvement of near and intermediate vision.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Uncorrected Near Visual Acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Percent of subjects who achieved UCNVA of 20/40 or better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Near Uncorrected Visual Acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>AcuFocus Corneal Inlay</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AcuFocus Corneal Inlay</intervention_name>
    <description>Inlay implanted in cornea for improvement of near vision</description>
    <arm_group_label>AcuFocus Corneal Inlay</arm_group_label>
    <other_name>AcuFocus Corneal Inlay ACI 7000 PDT</other_name>
    <other_name>AcuFocus KAMRA inlay</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be natural emmetropes needing a minimum magnitude of +1.00D to +2.50D of
             reading add.

          2. Subjects must have uncorrected near visual acuity worse than 20/40 and better than
             20/100 in the eye to be implanted.

          3. Subject must have distance visual acuity correctable to at least 20/20 in both eyes.

          4. Subjects must have a preoperative spherical equivalent of plano defined as +0.50D to
             -0.75D with no more than 0.75D of refractive cylinder as determined by cycloplegic
             refraction in the eye to be implanted.

        Exclusion Criteria:

          1. Subjects with a difference of &gt; 1.00D between the spherical equivalent manifest
             refraction and the spherical equivalent cycloplegic refraction.

          2. Subjects with anterior segment pathology, including cataracts, in the eye to be
             implanted.

          3. Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or
             any corneal abnormalities (including endothelial dystrophy, guttata, recurrent corneal
             erosion, etc.) in the eye to be implanted.

          4. Subjects with ophthalmoscopic signs of keratoconus (or keratoconus suspect) in the eye
             to be implanted.

          5. Subjects with a history of chronic dry eye not responding to therapy.

          6. Subjects with distorted or unclear corneal mires on topography maps of the eye to be
             implanted.

          7. Subjects who require canthotomy to generate a corneal flap in the eye to be implanted.

          8. Subjects with macular degeneration, retinal detachment, or any other fundus pathology
             that would prevent an acceptable visual outcome in the eye to be implanted.

          9. Subjects who have undergone previous intraocular or corneal surgery including cataract
             and LASIK surgery.

         10. Subjects with a history of herpes zoster or herpes simplex keratitis.

         11. Subjects who have a history of steroid-responsive rise in intraocular pressure,
             preoperative IOP &gt; 21 mmHg, glaucoma, or is a glaucoma suspect.

         12. Subjects with a history of diagnosed diabetes, autoimmune disease, connective tissue
             disease, or clinically significant atopic syndrome.

         13. Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that
             may affect wound healing, and any immunocompromised subjects.

         14. Subjects who are using ophthalmic medication(s) other than artificial tears for
             treatment of any ocular pathology including ocular allergy.

         15. Subjects using systemic medications with significant ocular side effects.

         16. Subjects who are pregnant, lactating, or of child-bearing potential and not practicing
             a medically approved method of birth control.

         17. Subjects with known sensitivity to planned study concomitant medications.

         18. Subjects who are participating in any other ophthalmic drug or device clinical trial
             during the time of this clinical investigation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Perry Binder, MD</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>Vista Laser Eye Clinics</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3185</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Institute</name>
      <address>
        <city>Bondi Junction</city>
        <zip>2022</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus Medizinische Privat-Universität, PMU, Universitätsklinikum</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-Augenklinik, Department of Ophthalmology</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fendalton Eye Clinic</name>
      <address>
        <city>Fendalton</city>
        <state>Christchurch</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Eye</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore National Eye Centre</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optical Express</name>
      <address>
        <city>London</city>
        <zip>W1G 9AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.acufocus.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <results_first_submitted>July 20, 2016</results_first_submitted>
  <results_first_submitted_qc>December 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 6, 2017</results_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Presbyopia</keyword>
  <keyword>Accommodation</keyword>
  <keyword>Near visual acuity</keyword>
  <keyword>LASIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>119 participants were consented for the study (enrolled), and 118 subsequently were implanted with the device (started) for the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AcuFocus Corneal Inlay</title>
          <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients between 45 and 60 years of age with presbyopia</population>
      <group_list>
        <group group_id="B1">
          <title>AcuFocus Corneal Inlay</title>
          <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
AcuFocus Corneal Inlay ACI 7000PDT: Inlay implanted in cornea for improvement of near vision</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Singapore</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Uncorrected Near Visual Acuity</title>
        <description>Percent of subjects who achieved UCNVA of 20/40 or better.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AcuFocus Corneal Inlay</title>
            <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Uncorrected Near Visual Acuity</title>
          <description>Percent of subjects who achieved UCNVA of 20/40 or better.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of Near Uncorrected Visual Acuity</title>
        <description>Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AcuFocus Corneal Inlay</title>
            <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of Near Uncorrected Visual Acuity</title>
          <description>Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months, 6 months, 1 year, 2 years,3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AcuFocus Corneal Inlay</title>
          <description>Implantation of the AcuFocus Corneal Inlay in emmetropic presbyopic patients.
AcuFocus Corneal Inlay ACI 7000PDT: corneal inlay</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Stromal thinning secondary to abnormal healing response to corneal trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to bike accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization secondary to prostatectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hip replacement surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial punctate keratitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Vision</sub_title>
                <description>Decrease in BCDVA greater than 2 lines month 3 and later</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Cornea</sub_title>
                <description>Corneal edema</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Intraocular Pressure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Limbal foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Corneal abrasion/erosion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Foreign bodies over inlay with anterior corneal surface defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Lens</sub_title>
                <description>Cataract</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Meibomian Gland Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Partial sidecut at inner edge of mask</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Conjunctival Cyst</sub_title>
                <description>Fellow Eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Upper eyelid chalazion</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Admission to hospital for severe headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Increased blood sugar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Scleroderma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Chest Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Non-insulin-dependent diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Benign Prostate Hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Flap complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Secondary Surgical Intervention</sub_title>
                <description>Inlay recentration</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Secondary Surgical Intervention</sub_title>
                <description>Epithelial ingrowth removal</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
              <event>
                <sub_title>Knee injury &amp; surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="118"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eugenia Thomas, Director Clinical Trials</name_or_title>
      <organization>AcuFocus, Inc</organization>
      <phone>949/585-9511 ext 129</phone>
      <email>nthomas@acufocus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

